Form 4: Eli Lilly Director Acquires Shares Under Directors' Deferral Plan

Director Juan R. Luciano acquired 17.304 shares of Eli Lilly & Co common stock on February 18, 2025, under the company's Directors' Deferral Plan.

Summary

• On February 18, 2025, Juan R. Luciano, a director of Eli Lilly & Co, acquired 17.304 shares of common stock.
• The acquisition was made under the Lilly Directors' Deferral Plan as a deferral of cash compensation.
• The price per share was $857.2.
• Following the transaction, Luciano directly owns 16,228.587 shares of Eli Lilly & Co.
• The acquired shares will be settled in common stock after Luciano's separation from service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares under a deferral plan is generally a good sign, indicating confidence in the company's future performance. However, it's a routine transaction.

Positives

• Director's participation in the Directors' Deferral Plan signals confidence in the company's future.
• Increased share ownership aligns the director's interests with those of other shareholders.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

Directors' share acquisitions are common and often viewed positively, indicating confidence in the company's prospects. Deferral plans are a typical way to align director compensation with long-term shareholder value.

Comparison to Industry Standards

• Director compensation plans, including stock deferral programs, are common across publicly traded companies, particularly in the pharmaceutical industry.
• Companies like Pfizer, Johnson & Johnson, and Merck also have similar programs to align director and shareholder interests.
• The specific details of these plans (deferral rates, vesting schedules, etc.) vary by company.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with shareholder value.
• There is no significant impact on employees, customers, suppliers, or creditors.

Key Dates